Evidence map›Paper›PMID 41815775›Full record

ArticleLeukemia research reports2026

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report.

Tung-Lin Chiang, John Frater, Amanda Cashen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tung-Lin ChiangDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
John FraterDivision of Anatomic and Molecular Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Amanda CashenDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing survival benefits over traditional chemoimmunotherapy. Richter transformation is the transformation of CLL/SLL into an aggressive lymphoma, typically necessitating an immediate start of treatment. This case report presents a CLL/SLL patient developing pathology-proven Richter transformation after a short hold of the BTK inhibitor, without clinical evidence of disease progression. This case also demonstrates that the pathology-only Richter transformation after a pause of the BTK inhibitor can respond to resumption of the inhibitor, without the addition of intensive chemotherapy.

Indexed as

Bruton tyrosine kinase inhibitorChronic lymphocytic leukemiaIbrutinibRichter-like transformationRichter transformationSmall lymphocytic lymphoma

Identifiers

PMID41815775
PMCPMC12972533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.